BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 12-08-2022
14.64 USD   +1.88%
05/08BIOCRYST PHARMACEUTICALS, INC. : Oppenheimer is niet langer positief gestemd
MM
05/08BIOCRYST PHARMACEUTICALS, INC. : Barclays herhaalt het Neutraal advies
MM
05/08BIOCRYST PHARMACEUTICALS, INC. : Evercore ISI verlaagt advies naar Neutraal
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op BIOCRYST PHARMACEUTICALS, INC.
09/08NORTH AMERICAN MORNING BRIEFING : Stocks to -2-
05/08BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
04/08BIOCRYST PHARMACEUTICALS : Second Quarter 2022 Conference Call
04/08SECTOR UPDATE : Health Care Stocks Slipping Ahead of Thursday Close
04/08SECTOR UPDATE : Health Care Stocks Still Struggling in Thursday Markets
04/08SECTOR UPDATE : Health Care Stocks Sputtering Despite Surging Biotechs
04/08BioCryst Pharmaceuticals Reports Wider Q2 Loss, Resumes Enrollment in BCX9930 Clinical ..
04/08BioCryst Pharma Shares Rise 21% After FDA Drops Partial Hold on BCX9930
04/08TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2022
04/08BIOCRYST : Q2 Earnings Snapshot
04/08BIOCRYST PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results and Upcoming Key ..
04/08Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q2 Revenue $65.5M
04/08BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
04/08Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022
04/08BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
04/08BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six ..
04/08BioCryst Resumes Enrollment in BCX9930 Clinical Program
04/08BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program
21/07BioCryst to Report Second Quarter 2022 Financial Results on August 4
18/07BioCryst to Present at Upcoming Investor Conference
15/07BioCryst to Present at Upcoming Investor Conference
04/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01/07BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack ..
23/06BioCryst Announces ORLADEYO (berotralstat) Data to be Presented at European Academy of ..
22/06BioCryst Announces ORLADEYOģ (berotralstat) Data to be Presented at European Academy of..
22/06BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy ..
10/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin..
09/06BioCryst Pharmaceuticals, Inc. - FDA Grants Fast Track Designation for BioCryst's ALK-2..
09/06BioCryst Pharmaceuticals Taps Pint Pharma as Commercial Partner for Orladeyo Drug in La..
09/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYOģ (berotralstat) in Lati..
08/06BioCryst's BCX9250 Secures Fast Track Designation from the US Food and Drug Administrat..
08/06BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
08/06Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 In..
08/06FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250
08/06BioCryst Pharma Gets Fast Track Designation for BCX9250
07/06BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Ma..
07/06BioCryst Pharmaceuticals Says Swiss Drug Regulator Approves Orladeyo to Prevent Angioed..
07/06BioCryst Announces Approval of ORLADEYOģ (berotralstat) by Swissmedic
07/06Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swis..
07/06BioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral ..
06/06BioCryst Pharmaceuticals Gets Canada's Approval of Oral Treatment to Prevent Hereditary..
06/06BioCryst Announces Health Canada has Authorized ORLADEYOģ (berotralstat), the Only Oral..
06/06Biocryst Announces Health Canada Has Authorized Orladeyoģ (Berotralstat), the Only Oral..
01/06BioCryst to Present at Upcoming Investor Conferences
10/05TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Co..
09/05BioCryst to Present at Upcoming Investor Conferences
09/05BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
06/05BioCryst to Present at Upcoming Investor Conferences
05/05BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
05/05TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
05/05Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q1 Revenue $49.9M, vs. Street Es..
05/05BIOCRYST : Q1 Earnings Snapshot
05/05BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
05/05BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
05/05BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
05/05BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022
04/05BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27/04BioCryst Pharmaceuticals' BCX9250 Drug Candidate Secures Access to EU's PRIME Program; ..
27/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27/04European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ..
21/04BioCryst to Report First Quarter 2022 Financial Results on May 5
18/04BioCryst Pharmaceuticals Shares Drop Midday Following Barclays Downgrade
14/04TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Con..
12/04NORTH AMERICAN MORNING BRIEFING : Stocks Waver, -3-
11/04BioCryst to Present at Upcoming Investor Conference
11/04BIOCRYST PHARMACEUTICALS : Regulation FD Disclosure - Form 8-K
11/04BIOCRYST PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
08/04SECTOR UPDATE : Health Care Stocks Enjoy Late Uptick
08/04Top Midday Decliners
08/04SECTOR UPDATE : Health Care Stocks Firming in Mostly Higher Market
08/04BioCryst Suspends Patient Enrollment in Clinical Trials for BCX9930; Shares Tumble
08/04BIOCRYST PHARMACEUTICALS : Pauses Enrollment in BCX9930 Clinical Trials - Form 8-K
08/04BIOCRYST PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op BIOCRYST PHARMACEUTICALS, INC.